

# Richard A Burkhart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3170333/publications.pdf>

Version: 2024-02-01

85  
papers

3,066  
citations

218592

26  
h-index

182361

51  
g-index

86  
all docs

86  
docs citations

86  
times ranked

4580  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.	0.7	11
2	The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence After Surgical Resection. <i>Annals of Surgery</i> , 2022, 275, 1165-1174.	2.1	15
3	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 378-385.	2.1	50
4	Solving for Chemotherapeutic Sensitivity: Adapting "Black Box" Methods to Study Patient-Derived Tumor Organoids. <i>Annals of Surgical Oncology</i> , 2022, 29, 4-6.	0.7	1
5	Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. <i>Surgery</i> , 2022, 171, 1379-1387.	1.0	7
6	Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. <i>World Journal of Surgery</i> , 2022, 46, 667-677.	0.8	5
7	Incidence and Contemporary Management of Delayed Bleeding Following Pancreaticoduodenectomy. <i>World Journal of Surgery</i> , 2022, 46, 1161-1171.	0.8	6
8	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	0.8	7
9	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468.	0.7	12
10	Nontumor related risk score: A new tool to improve prediction of prognosis after hepatectomy for colorectal liver metastases. <i>Surgery</i> , 2022, 171, 1580-1587.	1.0	2
11	Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases. <i>JAMA Surgery</i> , 2022, 157, e221819.	2.2	16
12	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
13	Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4192-TPS4192.	0.8	1
14	Perioperative Outcomes of Robotic Pancreaticoduodenectomy: a Propensity-Matched Analysis to Open and Laparoscopic Pancreaticoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1795-1804.	0.9	43
15	Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 428-435.	0.9	8
16	Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin. <i>Journal of Surgical Oncology</i> , 2021, 123, 416-424.	0.8	12
17	Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the "halo sign" and "string sign". <i>Surgery</i> , 2021, 169, 1026-1031.	1.0	37
18	Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. <i>Hpb</i> , 2021, 23, 575-586.	0.1	10

#	ARTICLE	IF	CITATIONS
19	An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). <i>Annals of Surgical Oncology</i> , 2021, 28, 3125-3134.	0.7	28
20	Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. <i>Journal of the American College of Surgeons</i> , 2021, 232, 405-413.	0.2	39
21	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. <i>Cancer Letters</i> , 2021, 497, 221-228.	3.2	10
22	The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status. <i>Annals of Surgery</i> , 2021, 273, 1165-1172.	2.1	33
23	Clinical and molecular features of adenosquamous pancreatic cancer (ASQ): A distinct histological subtype.. <i>Journal of Clinical Oncology</i> , 2021, 39, 426-426.	0.8	0
24	Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 443-443.	0.8	1
25	Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. <i>Hpb</i> , 2021, 23, 468-474.	0.1	6
26	Postoperative biliary anastomotic strictures after pancreaticoduodenectomy. <i>Hpb</i> , 2021, 23, 1716-1721.	0.1	8
27	A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4134-4134.	0.8	5
28	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. <i>JCI Insight</i> , 2021, 6, .	2.3	10
29	Abstract 2372: Mechanisms of microRNA-21 dysregulation in pancreatic ductal adenocarcinoma (PDAC). , 2021, , .		0
30	Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. <i>World Journal of Surgery</i> , 2021, 45, 3157-3164.	0.8	1
31	Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 891-903.	5.7	147
32	Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 3149-3159.	0.9	12
33	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 714-715.	0.7	1
34	Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 206-214.	1.4	18
35	Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 162-169.	2.1	25
36	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>Oncolmmunology</i> , 2021, 10, 2001159.	2.1	10

#	ARTICLE	IF	CITATIONS
37	Abstract PO-111: A human single-cell RNA sequencing atlas of pancreatic ductal adenocarcinoma enables harmonized cell type calling and comprehensive analyses of potential intercellular signaling. , 2021, , .		0
38	Surgical Resection of 78 Pancreatic Solid Pseudopapillary Tumors: a 30-Year Single Institutional Experience. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 874-881.	0.9	23
39	Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 841-848.	0.9	4
40	Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1590-1596.	0.9	19
41	The impact of high body mass index on patients undergoing robotic pancreatectomy: A propensity matched analysis. <i>Surgery</i> , 2020, 167, 556-559.	1.0	9
42	Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2020, 272, 1118-1124.	2.1	58
43	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. <i>Cancer Letters</i> , 2020, 493, 245-253.	3.2	18
44	Mesoportal bypass, interposition graft, and mesocaval shunt: Surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. <i>Surgery</i> , 2020, 168, 1048-1055.	1.0	22
45	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.2	11
46	Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image Guided Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. <i>Practical Radiation Oncology</i> , 2020, 10, e508-e513.	1.1	11
47	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. <i>Cancer Discovery</i> , 2020, 10, 1566-1589.	7.7	90
48	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 427-435.	2.1	61
49	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. <i>Cancer Research</i> , 2020, 80, 2804-2817.	0.4	58
50	Radical antegrade modular pancreatectomy versus standard distal pancreatectomy for pancreatic cancer, a dual-institutional analysis. <i>Chinese Clinical Oncology</i> , 2020, 9, 54-54.	0.4	5
51	Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 17-17.	1.2	5
52	Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway. <i>Journal of the American College of Surgeons</i> , 2019, 228, 415-424.	0.2	38
53	Psychosocial Risks are Independently Associated with Cancer Surgery Outcomes in Medically Comorbid Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 936-944.	0.7	13
54	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	3.2	118

#	ARTICLE	IF	CITATIONS
55	Missed psychosocial risk factors during routine preoperative evaluations are associated with increased complications after elective cancer surgery. <i>Surgery</i> , 2019, 166, 177-183.	1.0	2
56	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.	3.2	57
57	Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. <i>Hpb</i> , 2019, 21, 998-1008.	0.1	21
58	Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1674-1683.	0.5	62
59	A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 973-984.	0.5	11
60	Negative Pressure Wound Therapy for Surgical-site Infections. <i>Annals of Surgery</i> , 2019, 269, 1034-1040.	2.1	86
61	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	0.9	54
62	Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 1154-1162.	2.1	222
63	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.	2.1	280
64	The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1350-1357.	0.9	15
65	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.	2.1	139
66	Lessons learned from 29 lymphoepithelial cysts of the pancreas: institutional experience and review of the literature. <i>Hpb</i> , 2018, 20, 612-620.	0.1	13
67	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. <i>JAMA Surgery</i> , 2018, 153, e180996.	2.2	151
68	Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping. <i>Methods in Molecular Biology</i> , 2018, 1787, 253-261.	0.4	11
69	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status. <i>Annals of Surgery</i> , 2018, 268, 408-420.	2.1	125
70	Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2475-2483.	0.7	77
71	Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. <i>Surgical Oncology</i> , 2017, 26, 138-145.	0.8	49
72	Role of exosomes in treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2017, 26, 219-228.	0.8	27

#	ARTICLE	IF	CITATIONS
73	Surgical Site Infections Following Pancreaticoduodenectomy. <i>Hpb</i> , 2017, 19, 1131.	0.1	1
74	Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772923.	0.7	24
75	Preoperative risk factors for conversion and learning curve of minimally invasive distal pancreatectomy. <i>Surgery</i> , 2017, 162, 1040-1047.	1.0	33
76	The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. <i>Hpb</i> , 2017, 19, 825-831.	0.1	35
77	Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. <i>Cell</i> , 2017, 170, 875-888.e20.	13.5	339
78	Role of Hepatectomy for Hepatocellular Carcinoma in the Era of Transplantation and Locoregional Therapy. <i>Digestive Disease Interventions</i> , 2017, 01, 094-104.	0.3	1
79	Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience. <i>Journal of Surgical Research</i> , 2017, 219, 238-243.	0.8	11
80	Laparoscopic hepatectomy for hepatocellular carcinoma: are oncologic outcomes truly superior to an open approach?. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, i14-, 200-202.	0.7	5
81	Geographical variation and trends in outcomes of laparoscopic spleen-preserving distal pancreatectomy with or without splenic vessel preservation: A meta-analysis. <i>International Journal of Surgery</i> , 2017, 45, 47-55.	1.1	20
82	Laparoscopic total pancreatectomy with islet autotransplantation for chronic pancreatitis. <i>Journal of Visualized Surgery</i> , 2016, 2, 121-121.	0.2	5
83	Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1400-1404.	0.9	15
84	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. <i>Surgical Oncology</i> , 2016, 25, 190-199.	0.8	12
85	Multidisciplinary management and the future of treatment in cholangiocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 255-267.	0.5	2